research Alopecia areata: Time for position statement to include new systemic therapeutic advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
Search
for
Sort by
Research
150-180 / 1000+ results research Autoinmune Alopecia/Alopecia Areata
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
research Alopecia Areata - Current and Emerging Therapies
New treatments like JAK inhibitors offer hope for hair regrowth in severe alopecia areata.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Clinical guidelines of ukrainian hair research society. diagnosis and treatment of alopecia areata
The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
research 84 Partial restoration of scalp microbiota in alopecia areata with JAK inhibitors
JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
research Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
research From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
research Off-Label Treatment of Alopecia Areata—Retrospective Study
Off-label treatments are heavily used for alopecia areata due to limited approved options.
research Alopecia universalis following human papillomavirus vaccine administration: a case report
A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma
Axitinib treatment turned a man's grey hair back to black.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.